ArticleMedicine2025
Ropivacaine and lidocaine-induced central nervous system toxicity following brachial plexus block in two uremic patients.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleRopivacaine and lidocaine are amide local anesthetics (LAs) commonly used for brachial plexus block, and with lower central nervous system (CNS) toxicity and cardiovascular toxicity than bupivacaine. However, emerging evidence suggests that neurotoxicity associated with these LAs may still occur, particularly in high-risk populations such as uremic patients, who may exhibit altered drug metabolism and increased susceptibility to adverse effects. Therefore, we aimed to report and analyze 2 cases of CNS toxicity following ropivacaine and lidocaine administration in this population. The findings will contribute to a better understanding of the safety profile of these LAs in uremic patients. PATIENT CONCERNS: We describe 2 cases of CNS toxicity in uremic patients following brachial plexus blocks induced by a total of 20 mL 0.375% ropivacaine mixed with 1% lidocaine. Both patients became unconscious and failed to respond to verbal after brachial plexus blocks. However, their vital signs were stable and no signs of cardiovascular toxicity were observed. DIAGNOSES: The 2 patients were diagnosed with CNS toxicity following brachial plexus block. The diagnosed of CNS toxicity was based on:(1) Unconscious and failed to respond to verbal after LAs injection.(2) Exclusion of alternatives: no hypoglycemia; normal arterial blood gases; absence of focal neurological signs suggesting stroke or epilepsy.(3) Supporting factors: reduced renal clearance may lead to larger plasma concentrations of LAs in uremic patients; hypertension likely resulted from sympathetic activation during CNS toxicity.
interventionsBoth patients were given oxygen via a mask at a rate of 3 L/min, standard monitoring, and close observation. Arterial blood gas analysis was immediately conducted. OUTCOMES: They were both fully conscious 2 hours after the brachial plexus block. Vascularized injection sites, uremic status, preexisting cardiac dysfunction, and the mixing of the 2 local anesthetics may be the reasons for the occurrence of the CNS toxicity. LESSONS: When performing peripheral nerve block, it is necessary to identify whether there are risk factors that increase the incidence of local anesthetic systemic toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.